|
|
 |
November 13, 2008 |
Now Available:
Watch video podcasts of press conference footage from ACR 2008
CME Meetings:
MSK Report provides cutting-edge scientific updates through biweekly and special edition newsletters, in-depth interviews, and on-location coverage of medical meetings, making it the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
ACR 2008: Visit MSK Report's dedicated ACR 2008 page
for complete coverage of the American College of Rheumatology's Annual Scientific Meeting, including press conference videos and interviews with presenters.
ACR 2008: H. pylori Suspected in Oral Bisphosphonate Intolerance, SSc Stomach Problems
Helicobacter pylori infects nearly half of patients who cannot tolerate oral bisphosphonates and over 80% of systemic sclerosis patients. Treating H. pylori might reduce GI problems and increase treatment options in these and other rheumatoid conditions...
ACR 2008: Pegloticase Offers Hope to Patients With Worst Types of Gout
Pegloticase (Puricase, Savient Pharmaceuticals, Inc.) performed well in two Phase III studies...
ACR 2008: Parathyroid Hormone Patch May Increase BMD and Adherence
A new patch that delivers parathyroid hormone (PTH) may increase spine and hip BMD and avoid some of the compliance issues seen with subcutaneous daily injections of PTH...
Arthritis: Il-6 Blockade Helps Move RA Patients TOWARD Remission
Interleukin-6 blockade with tocilizumab (Actemra), when combined with conventional DMARDs, safely and effectively reduces rheumatoid arthritis joint and systemic symptoms in patients were not helped by DMARDs alone...
BioPharm Business: Novartis' ACZ885 Phase III Data Show Rapid, Sustained Clinical Remission in Children and Adults with CAPS, a Group of Rare, Potentially Life-Threatening Autoinflammatory Diseases
Novartis also announced that preliminary results of a phase I/II study in systemic juvenile idiopathic arthritis showed that most patients treated with ACZ885 achieved substantial clinical improvement within 15 days...